HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Liquid biopsy techniques, which analyze biomarkers in blood or other body fluids, are emerging as a powerful tool in cancer research and clinical practice. These non-invasive methods allow for the detection of genetic mutations, tumor DNA, and other biomarkers associated with cancer, providing a snapshot of the tumor’s genetic makeup without the need for invasive tissue biopsies. In addition, liquid tumor models, along with computational simulations (in silico), offer the ability to study cancer in a more dynamic and real-time manner. By simulating tumor growth and treatment responses virtually, researchers can test potential therapies and predict outcomes more accurately. This combination of liquid biopsy and in silico models could lead to more personalized, timely, and effective treatment strategies for cancer patients.
